Question 1

What is CNS-3D Technology?

Accepted Answer

CNS-3D Technology is a portfolio of human iPSC-derived cortical organoids for preclinical safety and efficacy studies. Products incorporate various cell types—including neurons, astrocytes, microglia, and oligodendrocytes—for functional assessment of neurotoxicity, neuroinflammation, remyelination, and drug efficacy.

Each model is designed for functional assessment and can be paired with complementary structural, molecular, and biochemical endpoints, enabling researchers to select the model best aligned to their research objectives.

Question 2

What CNS-3D models are available?

Accepted Answer

CNS-3D Technology includes CNS-3D Brain Organoids, CNS-3D Inflammatory Organoids, CNS-3D Myelinated Organoids, and the CNS-3D Induced Alzheimer's Model. Brain Organoids support functional studies of CNS toxicity and drug efficacy; Inflammatory Organoids incorporate microglia for neuroimmune studies; Myelinated Organoids incorporate oligodendrocyte lineage cells for myelin biology; and the Induced Alzheimer's Model combines CNS-3D Inflammatory Organoids with exogenous amyloid beta oligomers and a defined protocol for anti-amyloid beta efficacy studies.

Question 3

What makes CNS-3D different from other 3D brain cell culture?

Accepted Answer

CNS-3D Technology is designed for reproducible preclinical studies, with standardized production, strict quality control, and assay-ready formats. The portfolio includes functional brain organoids as well as the only commercially available 3D brain organoid models incorporating microglia or oligodendrocyte lineage cells. This enables researchers to select fit-for-purpose human CNS models that align with their study needs.

Question 4

What types of studies can CNS-3D Technology support?

Accepted Answer

A broad range of safety and efficacy studies are supported, including neurotoxicity screening, neuroinflammation, Alzheimer’s, myelination, and gene therapy vector assessment. CNS-3D can be applied across diverse therapeutic modalities, including small molecules, ASOs, and gene therapies. For programs that require a different cellular composition, disease context, or assay design, custom CNS-3D models can be developed to align with specific research goals.

Question 5

What kind of data does CNS-3D generate?

Accepted Answer

CNS-3D models are designed for functional assessment of neuronal network activity using calcium imaging. Depending on the study objective, researchers can pair functional endpoints with structural imaging, viability and cytotoxicity assays, cytokine analysis, and molecular profiling to support drug safety and efficacy testing.

Question 6

What evidence supports CNS-3D for neurotoxicity assessment?

Accepted Answer

CNS-3D Brain Organoids have demonstrated superior performance in benchmarked CNS toxicity studies. In small molecule seizure risk prediction, CNS-3D achieved 83% sensitivity and 89% specificity, outperforming the best-published animal model benchmark by 13x. CNS-3D has also achieved 92% sensitivity and 92% specificity for ASO neurotoxicity prediction, supporting its use for more clinically predictive CNS toxicity assessment.

Question 7

How can researchers access 28bio brain organoid models?

Accepted Answer

CNS-3D models are available as assay-ready products, disease-focused models, or through CNS Services. Researchers can run studies in-house using CNS-3D Brain Organoids, Inflammatory Organoids, Myelinated Organoids, or the Induced Alzheimer's Model, or use CNS Services for study design, execution, and analysis. Custom models, endpoints, and assay designs can also be developed for specialized research programs.